NCT00034281View on ClinicalTrials.gov

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

September 30, 2003

Study Completion Date

September 30, 2003

Conditions
Breast NeoplasmPancreatic NeoplasmLung NeoplasmOvarian NeoplasmRenal Neoplasm
Interventions
DRUG

TAK-165

Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days.

Trial Locations (4)

78229

The Institute for Drug Development, San Antonio

78234

Brooke Army Medical Center/Drug Development Unit, San Antonio

78284

South Texas VA, Audie Murphy Division, San Antonio

85258

Arizona Cancer Center, Scottsdale

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY